Navigation Links
Potential Role of Natural Alkaloids in Combatting Memory Loss
Date:1/11/2012

hich necessitates less frequent dosing, and has shown no abuse potential in animal screening. In addition, anatabine is able to lower amyloid levels in animal models of Alzheimer's disease which become abnormally high as the disease progresses."  Dr. Mullan also commented that the Roskamp Institute is actively pursuing the use of anatabine as a support for memory loss, and will be initiating human studies to explore further this potential role for anatabine.

+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + +  + + ++ + + + + + + + + + + + + + + + + + + + +

Certain statements in this press release other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "continues," "likely," "may," "opportunity," "potential," "projects," "will," "expects," "plans," "intends" and similar expressions to identify forward-looking statements, whether in the negative or the affirmative. These statements reflect our current beliefs and are based on information currently available to us. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties, factors and contingencies include, without limitation, the challenges inherent in new product development initiatives through Star Tobacco and Rock Creek, the uncertaintie
'/>"/>

SOURCE Star Scientific
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
3. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
4. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
5. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
6. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
7. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
8. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
9. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
10. Potential Early Warning System for Lung Cancer Identified
11. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... for the fiscal third quarter 2014 after the market ... The Company will host a conference call for investors ... Time (10 a.m. Eastern Time). Investors may access the ...
(Date:7/29/2014)... PRINCETON, N.J., July 29, 2014  Covance Inc. (NYSE: ... second quarter ended June 30, 2014.  Net revenue was ... of 2013.  On a GAAP basis, the company reported ... quarter.  The company reported pro forma earnings per diluted ... of 2013. Pro forma results exclude asset impairment charges ...
(Date:7/29/2014)... 2014 New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. The study finds that the ...
Breaking Medicine Technology:Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... 11, 2012  Star Scientific, Inc. (NASDAQ: CIGX ) ... the Journal of Neurology suggests that nicotine patches ... a professor of psychiatry at Vanderbilt University Medical Center, led ... treatment among patients who had mild cognitive impairment – often ...
... ANGELES, Jan. 11, 2012 Decision Diagnostics Corp., ... developer of revolutionary  Smart phone centric e-health care ... provider of home medical supplies and point of ... leading fulfillment provider of direct to patient diabetes ...
Cached Medicine Technology:Potential Role of Natural Alkaloids in Combatting Memory Loss 2Potential Role of Natural Alkaloids in Combatting Memory Loss 3Potential Role of Natural Alkaloids in Combatting Memory Loss 4Medical IT and Diagnostic Product Company Decision Diagnostics Announces Patent Enforcement Strategy for Their Smart Phone Based EMR Technology 2
(Date:7/29/2014)... HealthDay Reporter TUESDAY, July ... on a task, various brain connections fire up. But ... with autism, according to a small new study. ... even less of this "brain flexibility," the researchers found. ... when children with autism are faced with new situations," ...
(Date:7/29/2014)... The Board of Governors of the State Bar ... Connie Akridge to serve as a trustee of ... the Foundation. Akridge served as President of the State Bar ... Holland & Hart in Las Vegas, providing tailored counsel on ... and healthcare clients for more than 25 years. She regularly ...
(Date:7/29/2014)... 2014 New high priced hepatitis C ... by a projected $2.9 to $5.8 billion next year, ... Milliman released today by the Pharmaceutical Care Management Association ... increase by as much as 8.6 percent in 2015 ... Sovaldi and Olysio. , The study finds that the ...
(Date:7/29/2014)... The Law Offices of Michael Cordova is proud to ... organization providing grief camps for kids, teens, adults, and families. ... clients experience from the death of a loved one. ... Stepping Stones of Hope, as they provide hope and healing ... also includes a monthly support group and a variety of ...
(Date:7/29/2014)... headache sufferers to record the severity and regularity of ... Griffith research study. , A new approach to the ... with their triggers and is being led by Professor ... Health program. , He has developed an approach designed ... their headaches called Learning to Cope with Triggers (LCT). ...
Breaking Medicine News(10 mins):Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 3Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2
... April 27 BioTrends is pleased to announce the ... SIMPONI (R) . Cenotcor ... for SIMPONI (R) (generic name: golimumab) ... anti-TNF-alpha therapy, SIMPONI is approved for the treatment of ...
... WASHINGTON, April 27 Speaker Nancy ... virus: "This afternoon, Majority Leader Hoyer and I were ... Obama Administration,s preparations to deal with the public health ... briefed us on the efforts that are being made ...
... 27 Speaker Nancy Pelosi released the following statement ... serve as Ambassador at Large and Global AIDS Coordinator:"President ... Ambassador at Large and Global AIDS Coordinator signals the ... Dr. Goosby is an excellent choice and is uniquely ...
... April 27 Young Innovations, Inc. (Nasdaq: YDNT ... 2009. Sales for the first quarter of 2009 were ... the $24.4 million reported in the first quarter of 2008. ... first quarter of 2009 from $4.6 million in the first ...
... BAX ), will host its annual shareholders meeting ... (10:30 a.m. Central Time)This call is being webcast by Thomson/CCBN ... http://www.baxter.com/ . The conference call ... It cannot be recorded or rebroadcast without Baxter,s permission.The webcast ...
... HSKA ) announces the following Webcast: (Logo: ... to Its Annual Meeting of Stockholders on the WebWhen: ... www.heska.com (click on the Annual Meeting of ... Live over the Internet -- Simply log on ...
Cached Medicine News:Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 2Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 3Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 4Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 5Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 6Health News:Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: